JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients by Irino, Tamotsu et al.
JAK2 V617F-Dependent Upregulation of PU.1 Expression
in the Peripheral Blood of Myeloproliferative Neoplasm
Patients
Tamotsu Irino
1,2, Munehiro Uemura
3, Humitsugu Yamane
4, Shigeto Umemura
1, Takahiko Utsumi
1,
Naoki Kakazu
4, Taku Shirakawa
2, Mitsuhiro Ito
2, Takayo Suzuki
1, Kazuo Kinoshita
3*
1Shiga Medical Center for Adults, Moriyama, Japan, 2Division of Medical Biophysics, Kobe University Graduate School of Health Science, Kobe, Japan, 3Shiga Medical
Center Research Institute, Moriyama, Japan, 4Department of Environmental and Preventive Medicine, Shimane University School of Medicine, Izumo, Japan
Abstract
Myeloproliferative neoplasms (MPN) are multiple disease entities characterized by clonal expansion of one or more of the
myeloid lineages (i.e. granulocytic, erythroid, megakaryocytic and mast cell). JAK2 mutations, such as the common V617F
substitution and the less common exon 12 mutations, are frequently detected in such tumor cells and have been
incorporated into the diagnostic criteria published by the World Health Organization since 2008. However, the mechanism
by which these mutations contribute to MPN development is poorly understood. We examined gene expression profiles of
MPN patients focusing on genes in the JAK–STAT signaling pathway using low-density real-time PCR arrays. We identified
the following 2 upregulated genes in MPN patients: a known target of the JAK–STAT axis, SOCS3, and a potentially novel
target, SPI1, encoding PU.1. Induction of PU.1 expression by JAK2 V617F in JAK2-wildtype K562 cells and its downregulation
by JAK2 siRNA transfection in JAK2 V617F-positive HEL cells supported this possibility. We also found that the ABL1 kinase
inhibitor imatinib was very effective in suppressing PU.1 expression in BCR-ABL1-positive K562 cells but not in HEL cells. This
suggests that PU.1 expression is regulated by both JAK2 and ABL1. The contribution of the two kinases in driving PU.1
expression was dominant for JAK2 and ABL1 in HEL and K562 cells, respectively. Therefore, PU.1 may be a common
transcription factor upregulated in MPN. PU.1 is a transcription factor required for myeloid differentiation and is implicated
in erythroid leukemia. Therefore, expression of PU.1 downstream of activated JAK2 may explain why JAK2 mutations are
frequently observed in MPN patients.
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Introduction
Genetic testing to diagnose cancer is now becoming a common
clinical practice. This trend is quite reasonable from the viewpoint
that cancer is a genetic disease. In 2008, the World Health
Organization incorporated genetic tests for the gene of Janus
kinase 2 (JAK2) V617F mutation and other functionally similar
mutations (such as JAK2 exon 12 mutations) into the diagnostic
criteria for myeloproliferative neoplasms (MPN), a collection of
hematological malignancies that include polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis [1]. It
has been reported that PV patients possess a homozygous JAK2
V617F mutation, while a heterozygous mutation is common in ET
patients [2]. Although such correlations indicate a dose effect of
these mutations on disease manifestation, the molecular mecha-
nism of this phenomenon remains unclear.
JAK kinases are cytoplasmic molecules that transmit signals
from cytokine receptors to signal transducer and activator of
transcription (STAT) transcription factors [3–5]. Since JAK2
mutations observed in MPN patients are known to exert their
effects by activating downstream signaling pathways leading to the
activation of target genes, it is possible that the effects of all types of
mutations observed in JAK2 and other functionally related genes,
such as myeloproliferative leukemia virus oncogene (MPL), funnel
into the activation of a common set of genes. If so, determination
of the mRNA abundance of such genes may be a substitute for the
laborious screening of possible genetic mutations.
In this study, we examined the expression profiles of 84 JAK–
STAT-related genes in peripheral blood samples taken from 26
MPN patients to determine molecular signatures of the activated
JAK–STAT signaling pathway. We found that the suppressor of
cytokine signaling 3 (SOCS3) expression was significantly elevated
in MPN patients with a JAK2 V617F mutation, suggesting that
SOCS3 mRNA in peripheral blood can be used as a biomarker for
diagnosis and assessment of MPN patients. In addition, we report
here a novel link between JAK2 and a hematopoietic transcription
factor, PU.1, which was verified using in vitro cell culture
experiments. As PU.1 is a regulator of proliferation and
differentiation of erythroid, myeloid, and lymphoid cells [6], the
effect of JAK2 mutations may be mediated partly through
upregulation of PU.1. In addition, through pharmacological
inhibition of c-abl oncogene 1 (ABL1) kinase, both PU.1 and
SOCS3 appeared to be regulated with a breakpoint cluster region
(BCR)-ABL1 fusion protein in K562 cells. In contrast to JAK2
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22148V617F-positive HEL cells, PU.1 and SOCS3 expression in K562
cells were JAK2-independent, suggesting that PU.1 and SOCS3
may be a common downstream target of oncogenic JAK2 and
ABL1 signaling.
Materials and Methods
Patients and Samples
Twenty-six patients diagnosed with MPN at Shiga Medical
Center for Adults in 2008 and 2009 and 11 healthy volunteers
were enrolled in this study (Supplementary Table S1). Genomic
DNA and total RNA were isolated from their peripheral blood
using a QuickGene DNA whole blood kit S (DB-S, Fuji Film,
Tokyo, Japan) and a RiboPure-Blood kit with RNAlater solution
(Applied Biosystems, Foster City, CA), respectively. Integrity of
DNA and RNA was verified by agarose gel electrophoresis and
capillary electrophoresis using Experion (Bio-Rad, Hercules, CA),
respectively. Written informed consent was obtained from all
participants, and samples were collected and analyzed. All
procedures were approved by the Ethical Committee of Shiga
Medical Center for Adults.
Mutation Analysis
The presence of a JAK2 V617F mutation was determined by the
following 3 methods: allele-specific PCR, quantitative allele-
specific PCR, and direct sequencing. Allele-specific PCR was
performed as reported previously [7]. Samples with a mutant-
specific band stronger than that of a mixture of genomic DNA
from HEL (V617F-type JAK2) and K562 (wild-type JAK2) cell
lines at a ratio of 1:99 was determined to be positive for a JAK2
mutation.
Quantitative allele-specific PCR was performed in triplicate in
18-ml reactions containing 16SYBR Premix Ex Taq II (Takara,
Otsu, Japan), 500 nM forward primer, 500 nM reverse primer,
and 36 ng genomic DNA using an Mx3000P real-time thermal
cycler (Agilent, Santa Clara, CA). The PCR conditions were as
follows: 95uC for 30 s, 40 cycles at 95uC for 15 s, and then 58uC
for 1 min, followed by a segment for dissociation curve analysis.
The wild-type and V617F alleles were amplified using the
following primer pairs: JAK2-ASPCR-F3 and JAK2-ASPCR-R2
for the wild-type allele, and JAK2-ASPCR-F4 and JAK2-ASPCR-
R2 for the V617F allele. Primer sequences are listed in
Supplementary Table S2. Standard curves were drawn using
defined copy numbers (7.2610
4, 7.2610
3, 7.2610
2, and 7.2610
1)
of PCR products prepared using primers JAK2-Frag-1F and
JAK2-Frag-1R for genomic DNA from HEL (template for the
V617F allele) and K562 (template for the wild-type JAK2 allele)
cells. The V617F mutation burden was calculated as the ratio of
the amount of V617F DNA to the sum of V617F and wild-type
DNA. The validity of this assay was confirmed by comparing these
results with those obtained using a commercially available kit
(JAK2 MutaQuant Kit, Ipsogen, New Haven, CT).
Direct sequencing was performed by sequencing the 364-bp
band by allele-specific PCR [7] from the primer JAK2-Seq-1R
using BigDye Terminator v1.1 and BigDye XTerminator with an
ABI PRISM 3130 sequencer (Applied Biosystems). Samples that
displayed clear upward T peaks at the wild-type G position (the
first position of codon 617) were determined to be V617F positive.
JAK2 exon 12 and MPL exon 10 mutations were also
determined by direct sequencing as described [8,9].
Quantitative PCR Assay
First-strand cDNA was synthesized using an iScript kit (Bio-
Rad) from peripheral blood total RNA and a PrimeScript RT
reagent kit with gDNA Eraser (Takara) from cell line RNA.
Expression profiles of JAK–STAT-related genes were analyzed
with a PCR array PHAS-039 (SABiosciences, Frederick, MD) and
RT2 Real-Time SYBR Green/ROX PCR master mix using an
Mx3000P cycler (Agilent). Statistical analysis of obtained Ct values
was performed using web-based software (RT2 Profiler) provided
by SABiosciences. Data obtained from 37 plates are listed in
Supplementary Table S3.
Quantitation of SOCS3, SOCS1, SPI1, hypoxanthine phosphor-
ibosyl-transferase 1 (HPRT1), and ribosomal 18S RNA was
performed in triplicate using SYBR Premix Ex Taq II (Takara)
for patient samples and SYBR Premix DimerEraser (Takara) for
cell line samples. The primer sequences for SOCS1 and SOCS3
were as reported previously [10]. The primers for SPI1
(HA102872-F and HA102872-R), HPRT1 (HA067805-F and
HA067805-R), and 18S (HA067799-F and HA067799-R) were
Table 1. Sample Category Statistics.
Category Age Female Male
Mutational
Burden (%)
WBC
(610
9/L)
RBC
(610
9/L) Hb (g/dL) Ht (%)
PLT
(610
9/L)
[0] [3.4,9.2]
[F 3500,5000;
M 4000,5600]
[F 10.9,14.7;
M 13.2,17.1]
[F 32.5,44.7;
M 38.6,50.7] [14.8,35.2]
PV 63614 6 6 64624 16666 3 3 0 61131 15624 8 666 2 7 6270
ET 63610 9 5 12614 7624 0 1 3 6646 13613 9 647 3 2 6259
ET+ 65611 6 2 21613 7614 2 0 8 6550 13614 0 626 1 3 6227
ET2 61610 3 3 0607 623 7 5 3 6722 13623 7 658 9 1 6222
Group 1 63615 3 6 76671 8 656 6 3 4 61070 16625 0 655 7 8 6285
Group 2 65611 9 2 22613 8634 5 9 3 6946 13614 1 636 5 2 6223
Group 3 61610 3 3 0607 623 7 5 3 6722 13623 7 658 9 1 6222
Control 48684 7
Mean value and standard deviation of age, mutation burden, white blood cell count, red blood cell count, hemoglobin, hematocrit, and platelet count at the time of
blood sampling are shown. Numbers of females and males are shown. The normal range of each test is indicated in the brackets with female (F) or male (M)-specific
ranges if available. Categories based on disease are: PV for polycythemia vera; ET for total cases of essential thrombocythemia; ET+ for V617F-positive ET, ET2 for V617F-
negative ET; and control for healthy volunteers. Group 1, group 2, and group 3 represents cases with a V617F mutation burden 50%–100%, 1%–50%, and 0%–1%,
respectively.
doi:10.1371/journal.pone.0022148.t001
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measuring 10-fold serial dilutions of cDNA samples derived from
the RNA of HEL cells. The mean values of measurements were
normalized by the amounts of HPRT1 and 18S for patient and cell
line samples, respectively. When we first attempted a calibration
using GAPDH mRNA, we found a 2-fold reduction of GAPDH in
V617F-expressing K562 cells compared with the mock transfec-
tant (data not shown). Therefore, we started using the more stable
HPRT1 for peripheral blood studies and 18S ribosomal RNA for
cell line studies. Statistical analyses were performed using Prism 4
software (Graph Pad, San Diego, CA).
Vector Construction
Coding sequences for wild-type and V617F-type JAK2 were
amplified from cDNA obtained from K562 and HEL cells,
respectively, using primers hJAK2-F-1F and hJAK2-F-1R.
Fragments obtained after digestion with SalI were inserted at the
XhoI site of pFB-da-Puro, a modified retrovirus vector of pFB
(Agilent), by insertion of an internal ribosomal entry site and a
puromycin resistance gene. The obtained plasmids for the wild-
type and V617F-type JAK2 retroviral vectors were designated
phJAK2-FBP and phJAK2V617F-FBP, respectively.
Cell Culture
K562 and HEL cell lines were obtained from the Japanese
Collection of Research Bioresources (Osaka, Japan) and cultured
in RPMI1640 medium with 10% fetal bovine serum and
penicillin/streptomycin (Invitrogen, Carlsbad, CA).
phJAK2-FBP, phJAK2V617F-FBP, or pFB-da-Puro were
cotransfected using FuGENE6 (Roche, Mannheim, Germany)
into HEK293T cells with pCL-Ampho (Imgenex, San Diego, CA)
to prepare a culture supernatant containing a JAK2 retrovirus,
which was used to infect K562 and HEL cells by spinfection. After
culturing in the presence of puromycin (0.6 mg/ml for K562 and
1.3 mg/ml for HEL) for 10–20 days, cells were lysed for RNA
extraction using a QuickGene RNA cultured cell kit S (RC-S, Fuji
Film).
Three types of siRNA for the human JAK2 gene and 2 negative
control siRNAs were purchased (Silencer Select siRNAs, Applied
Biosystems, s7649 as siRNA1, s7650 as siRNA2, s7651 as siRNA3,
negative control #1 as NC1, and negative control #2 as NC2).
Samples of 30 pmol of these siRNAs were transfected into 2610
6
HEL and K562 cells, using Nucleofector II (Amaxa, Ko ¨ln,
Germany) with a Cell Line Nucleofector Kit V (Amaxa) and a
Program X-005. Then, cells were transferred to 6-well plates
containing 4 ml of culture medium and maintained at 37uC under
Table 2. Differential expression of genes in the JAK–STAT
signaling pathway in MPN patients.
Gene Group 1 Group 2 Group 3
1 ACTB 10.9 7.1 (23.1)
2 SOCS3 7.5 2.2 (21.7)
3 JAK2 4.4 (2.7) (2.0)
4 JAK3 4.2 (2.0) (1.7)
5 FAS 4.1 (2.4) 2.7
6 SPI1 3.9 2.1 (1.6)
7 STAT5B 3.6 (1.5) (21.5)
8 IFNGR1 2.7 (1.6) (1.1)
9 SP1 2.6 (1.9) (1.3)
10 IRF9 2.6 (1.6) (21.1)
11 STUB1 2.4 (1.6) (1.8)
12 GAPDH 2.3 (21.2) 2.0
13 JUNB 2.2 (21.1) (21.3)
14 FCGR1A 2.1 (1.3) 22.2
15 STAT3 1.7 (1.5) (1.1)
16 SRC 21.6 (1.1) (1.3)
17 HMGA1 21.6 (21.2) (21.4)
18 HPRT1 21.8 (21.6) 21.5
19 IL2RA 21.9 (21.6) 21.8
20 CSF2RB 21.9 21.6 23.5
21 SOCS1 22.2 22.0 23.9
22 IL20 22.2 (1.0) (22.0)
23 TYK2 22.3 (21.4) 22.0
24 SOCS2 22.3 (21.4) (22.5)
25 EPOR 22.3 (21.5) 22.2
26 YY1 22.5 21.7 22.8
27 STAT1 22.5 (21.5) 22.6
28 SOCS4 22.5 (21.6) (22.5)
29 MMP3 22.5 (21.4) (22.8)
30 IL2RG 22.6 22.1 23.4
31 IL4 22.7 (21.6) (22.8)
32 SOCS5 22.7 (21.6) (22.8)
33 PTPRC 22.9 (21.8) 23.5
34 JAK1 22.9 (21.6) 22.5
35 USF1 23.3 21.7 22.8
36 OAS1 23.3 (21.5) (22.3)
37 SLA2 23.4 (21.3) (21.6)
38 IL6ST 23.5 (21.6) 24.7
39 MYC 23.6 (22.1) 22.1
40 IFNG 24.1 22.3 22.0
41 NR3C1 24.2 22.4 24.3
42 SMAD2 24.2 (21.7) 22.5
43 PPP2R1A 24.3 22.5 23.3
44 IRF1 24.5 22.1 24.5
45 GATA3 25.6 22.5 22.4
46 STAT2 25.8 22.2 23.8
47 IL10RA 26.4 22.6 24.5
48 CSF1R 28.2 22.9 23.6
49 SH2B1 28.7 23.4 25.2
Gene Group 1 Group 2 Group 3
50 RPL13A 29.1 23.3 24.0
51 SIT1 29.6 23.0 24.7
52 STAT4 211.0 23.6 25.3
53 A2M 211.3 23.7 23.8
Selected genes analyzed by JAK–STAT-related PCR array that showed
statistically significant (p,0.05) up- or downregulation between the group 1
and the control group are shown. The magnitude of differences for groups 2
and 3 are also shown. Positive and negative numbers indicate up- and
downregulation, respectively. Numbers in parentheses indicate a lack of
statistical significance (p.0.05) in comparison with the control group.
doi:10.1371/journal.pone.0022148.t002
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preparation on day 2.
JAK2-specific inhibitor AG490 (Merck, Darmstadt, Germany)
and ABL1 inhibitor imatinib (Toronto Research Chemicals, North
York, Canada) were purchased and dissolved as stocks at 10 mM
with dimethyl sulfoxide and 10 mM with phosphate-buffered
saline, respectively. The vehicle concentrations were the same for
all culture conditions. Cells were harvested on day 1 for JAK2
phosphorylation analysis and on days 1 and 2 for RNA
preparation.
Western Blotting
Cells were lysed on ice with RIPA buffer (50 mM Tris-Cl,
150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS)
supplemented with 16 Complete Protease Inhibitor Cocktail
(Roche) and 46Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich,
St. Louis, MO). Cell lysate cleared by centrifugation was resolved
by 4%–20% gradient polyacrylamide gel (Miniprotean TGX gel,
Bio-rad). Proteins were semi-dry transferred to Immobilon-CF
PVDF membrane (Millipore) and probed with specified antibodies
using a SNAP i.d. Protein Detection System (Millipore, Billerica,
MA). Bound antibodies were detected using either an infrared
fluorescence scanner, Odyssey (Li-cor, Lincoln, NE) or an LAS-
3000 mini CCD camera (Fuji). Quantitation of band intensity was
performed using Odyssey version 1.2 (Li-cor). Rabbit monoclonal
antibodies for human JAK2 (D2E12) and tyrosine 1007/1008-
phosphorylated JAK2 (C80C3) were purchased from Cell
Signaling (Danvers, MA). Rabbit polyclonal antibodies against
human elongation factor 2 (EF-2) were purchased from Santa
Cruz Biotechnology (sc-25634; Santa Cruz, CA). Alexa 680-
labeled anti-rabbit IgG antibodies (Invitrogen, Carlsbad, CA) and
horseradish peroxidase-labeled anti-rabbit IgG (Biosource, Ca-
marillo, CA) were purchased. Chemiluminescence reaction was
performed using ECL Plus reagent (GE Healthcare, Piscataway,
NJ).
Results
JAK2 V617F mutation analysis
Genomic DNA purified from peripheral blood samples from 26
patients with MPN, diagnosed at Shiga Medical Center for Adults
in 2008 and 2009, was analyzed to determine JAK2 V617F
mutation status. The results of these tests are listed with clinical
parameters in Supplementary Table S1. None of our patients had
JAK2 exon 12 or MPL mutations.
Expression profiles of genes related to the JAK–STAT
signaling pathway
Using total RNA purified from peripheral blood of 26 patients
and 11 healthy volunteers, expression profiles of 84 genes related
to JAK–STAT-mediated signaling were analyzed with a commer-
cially available PCR array (SABiosciences). The Ct-value data
were normalized and compared using a web-based analysis tool
provided by SABiosciences. The source Ct-value data are shown
in Supplementary Table S3. First, we classified our MPN patients
into 3 groups based on their JAK2 V617F mutation burden as
determined by quantitative allele-specific PCR. Group 1 com-
prised patients with a mutation load of 50%–100%, representing
most PV patients. Group 2 included patients with a mutation
burden of 1%–50%, representing approximately half of the ET
patients and 3 PV patients. Group 3 comprised patients with less
than a 1% mutation load, representing the JAK2 V617F-negative
Figure 1. Expression of SOCS3 and SOCS1 mRNA in MPN patients. A. SOCS3 mRNA levels in peripheral blood of MPN patients determined by
qPCR (not PCR array) were calibrated with quantities of HPRT1 mRNA and plotted against JAK2 V617F mutation burden. The values are represented
with an arbitrary unit. The line and p value for the slope were calculated based on a linear regression model. B. SOCS1 mRNA levels plotted as in A. C.
SOCS3 mRNA levels were plotted by disease category. Control represents the healthy volunteers, and ET2 and ET+ represent V617F-negative and
-positive ET patients, respectively. PV represents PV patients. The p values were calculated by a t-test. D. SOCS1 mRNA levels plotted as in C.
doi:10.1371/journal.pone.0022148.g001
PU.1 Upregulation in MPN
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group. The characteristics of the patient groups are listed in
Table 1.
We looked for differences in the gene expression profiles of
patients in group 1 and the control group and found that 14 genes
were upregulated more than 2-fold and 33 genes were downreg-
ulated more than 2-fold in group 1 patients compared with
controls, respectively (Table 2). Of the 14 upregulated genes in
group 1, 3 genes—b actin (ACTB), SOCS3, and spleen focus
forming virus proviral integration oncogene 1 (SPI1)—were also
upregulated in group 2. Therefore, these 3 genes appeared to be
strongly associated with the JAK2 V617F mutation. We focused on
SOCS3 and SPI1 in our subsequent studies.
Among the 14 genes that were downregulated more than 4-fold
in group 1, 13 of them (IFNG, NR3C1, PPP2R1A, IRF1, GATA3,
STAT2, IL10RA, CSF1R, SH2B1, RPL13A, SIT1, STAT4, and
A2M) were also significantly downregulated in the groups 2 and 3.
Only the downregulation of SMAD2 in group 2 was not statistically
significant (Table 2). Therefore, downregulation of these genes in
MPN patients appears to be independent of JAK2 V617F
mutation.
Re-analysis of SOCS3 expression
Elevated SOCS3 mRNA expression in JAK2 V617F-positive
MPN patients was confirmed by individual quantitative PCR
(qPCR) assay of peripheral blood cDNA samples from the 26
patients and 11 healthy volunteers. Expression levels of related
SOCS1 mRNA were also examined. As shown in Figure 1A, there
was a clear correlation between SOCS3 mRNA levels and JAK2
V617F mutation burden, while only a marginal correlation was
detected for SOCS1 mRNA levels (Figure 1B). In these analyses,
the control group was not included because of a lack of mutation
data. The samples were then classified into 4 groups based on
disease category and ET patients were divided into JAK2 V617F-
positive (ET+) and negative (ET2) groups. SOCS3 expression in
the PV and ET+ groups were significantly higher than those in the
ET2 and control groups (Figure 1C). The expression level of
SOCS3 was highest in PV patients and was moderately elevated in
ET+ patients, while ET2 patients showed the same level of
expression as the control group. For SOCS1 expression, there was
no significant difference among the PV, ET+, and control groups
(Figure 1D). However, ET2 patients appeared to have lower
SOCS1 expression compared with the PV and control groups. This
result is consistent with the qPCR array results showing a 4-fold
reduction in group 3 and a 2-fold reduction in both group 1 and
group 2 compared with the control group (Table 2).
Re-analysis of SPI1 expression
In the PCR array experiment, compared with the control
group, SPI1 mRNA was upregulated 3.9-, 2.1-, and 1.6-fold
among groups 1, 2, and 3, respectively (Table 2), suggesting a
correlation between the SPI1 expression level and the JAK2 V617F
mutation burden. This PCR array result was verified by individual
qPCR assay (Figure 2A). PV and ET+ patients had significantly
increased amounts of SPI1 mRNA in peripheral blood compared
to the control (Figure 2B).
Analysis of signal transduction for SPI1 expression
In zebrafish embryos, spi1 expression is reported to be
upregulated by a constitutively active jak2a mutant and reduced
by suppression of jak2a by morpholino antisense oligonucleotide
[11]. However, there are no reports on regulation of SPI1 by JAK2
in humans. Hence, we set up an experiment using in vitro cultured
cell lines to examine the role of JAK2 on the regulation of SPI1.
K562 is a cell line derived from chronic myelogenous leukemia,
which has a wild-type JAK2 gene. HEL is a cell line derived from
erythroid leukemia, which has a homozygous JAK2 V617F
mutation [12]. We retrovirally introduced wild-type and V617F-
type JAK2 transgenes and quantitated the expression levels of SPI1
mRNA. The amount of JAK2 protein in the retroviral infectant
increased in K562 cells but not in HEL cells (Figure 3A). As shown
in Figure 3B, K562 cells overexpressing JAK2 V617F exhibited 2-
fold upregulation of SPI1 mRNA compared with the mock
transfectant. Such upregulation was not observed for wild-type
JAK2 transfectants. The reason for the lack of JAK2 overexpres-
sion in HEL cells is unclear, but it can be speculated that higher
levels of JAK2 protein may be toxic to JAK2 V617F-harboring
cells.
We then examined the effect of JAK2 downregulation by
siRNA-mediated RNA interference (RNAi). Among the 3 types of
commercially available siRNA tested against JAK2, one (siRNA3)
was more effective than the other 2 in decreasing JAK2 protein
expression in both HEL and K562 cells (Figure 4A). qPCR
Figure 2. Expression of SPI1 mRNA in MPN patients. A. SPI1
mRNA levels in peripheral blood of MPN patients determined by qPCR
(not PCR array) were calibrated with quantities of HPRT1 mRNA and
plotted against JAK2 V617F mutation burden. The values are
represented with an arbitrary unit. The line and p value for the slope
were calculated based on a linear regression model. B. SPI1 mRNA levels
were plotted by disease category. Control represents the healthy
volunteers, and ET2 and ET+ represent V617F-negative and -positive ET
patients, respectively. PV represents PV patients. The p values were
calculated by a t-test.
doi:10.1371/journal.pone.0022148.g002
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siRNA with strongest inhibition for siRNA3 compared to negative
controls in HEL cells (Figure 4B). However, this SOCS3 mRNA
suppression was not observed in K562 cells. This indicates that
SOCS3 expression in K562 cells is not driven by JAK2 signaling.
When SPI1 mRNA quantitation was similarly performed, the
basal expression in HEL cells (control siRNA-transfected cells)
appeared to be 6-fold higher than that in K562 cells (Figure 4C).
In parallel with the SOCS3 result, SPI1 mRNA was downregulated
by siRNA3 transfection only in HEL cells and not in K562 cells.
High expression of SPI1 mRNA and its inhibition by JAK2-siRNA
transfection in HEL cells is consistent with the idea that SPI1 gene
is upregulated by V617F-type JAK2 in HEL cells.
Finally, we examined the effect of a JAK2 inhibitor AG490 on
SPI1 and SOCS3 expression. When the autophosphorylation of
JAK2 at tyrosines 1007 and 1008 was examined using a phospho-
JAK2-specific monoclonal antibody, HEL cells were found to
contain phosphorylated JAK2, probably due to the kinase-
activating V617F mutation. This phosphorylation was completely
abrogated after culturing for 24 h in the presence of 100 mM
AG490 (Figure 5A). The same JAK2 phosphorylation was
undetectable in K562 cells even in the absence of AG490. Then,
we examined the effects of AG490 on SOCS3 and SPI1 mRNA
expression. As shown in Figure 5B, treatment of HEL cells with
AG490 resulted in decreased expression of SOCS3 mRNA but not
SPI1 mRNA. The response of K562 cells to AG490 was different
from that of HEL cells. SOCS3 mRNA was slightly enhanced at
50 mM but moderately suppressed at 100 mM. SPI1 mRNA was
slightly enhanced by AG490 in a dose-dependent manner.
Since JAK2 activates downstream genes through STAT3 or
STAT5, and because both STAT3 and STAT5 are known to be
activated by ABL1 signaling [13,14], we tested an ABL1 inhibitor
imatinib as well. When HEL cells were treated with imatinib,
SOCS3 mRNA slightly increased in a dose-dependent manner,
while the SPI1 mRNA level did not change (Figure 5C). In
contrast, K562 cells treated with imatinib exhibited a significant
reduction in the amounts of both SOCS3 and SPI1 mRNA,
suggesting that the expression of SOCS3 and SPI1 is driven by
ABL1 signaling in K562 cells.
Both AG490 and imatinib reduced proliferation of K562 cells
but not HEL cells in a dose-dependent manner (Supplementary
Figure S1). Therefore, we cannot formally exclude a possibility
that suppression of SOCS3 and SPI1 expression by imatinib in
K562 cells is attributed to a nonspecific cytotoxicity of imatinib.
Discussion
In this study, we used quantitative allele-specific PCR to
determine the JAK2 V617F mutation burden in patients diagnosed
with PV or ET and found a high and moderate mutation burden,
respectively. These findings are consistent with previous reports
[2,7]. We also examined the expression profiles of 84 JAK–STAT-
related genes using a commercially available PCR array and
searched for genes that were differentially expressed among
patient groups with different mutation burdens and/or clinical
diagnoses. We found that SOCS3 and SPI1 expression were
significantly elevated in JAK2 V617F-positive patients.
SOCS3 belongs to the SOCS family of proteins that mediate
negative-feedback inhibition of the JAK–STAT pathway [15].
SOCS3 expression is induced by erythropoietin, granulocyte-
colony stimulating factor (G-CSF), interleukin-6 (IL-6), leukemia
inhibitory factor, IL-23, and leptin. Ligand-induced dimerization
of receptor tyrosine kinases activates JAK2 and subsequently
STAT3, STAT5A, and STAT5B, which translocate to the nucleus
and transactivate transcription of many target genes, including
SOCS3. The induced SOCS3 protein in turn binds to phosphor-
ylated tyrosine residues in the cytoplasmic tails of the same
receptors that triggered SOCS3 induction and suppresses JAK2
Figure 3. Induction of SPI1 mRNA in K562 cells overexpressing V617F-type JAK2. A. Western blots showing the amounts of JAK2 protein
inK562 and HEL cells infected with retrovirus vector encoding either wild-type (JAK2 WT) or V617F-type JAK2 (JAK2 V617F) or a mock vector (vector)
and maintained in the presence of puromycin. The intensities of bands were calibrated with the band intensities of elongation factor 2 (EF-2) protein.
Fold over-expression is shown below as the value for the mock infectant as 1. The results of two independent infections are shown under
experiments (exp.) 1 and 2. Alexa 680-labeled secondary antibodies were used. B. SPI1 mRNA levels in K562 cells prepared by the retroviral infection
shown in A, along with those in non-infected K562 and HEL cells. The results were calibrated with 18S ribosomal RNA amount and represented with
an arbitrary unit.
doi:10.1371/journal.pone.0022148.g003
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promoting proteasomal degradation of JAK2.
Upregulation of SOCS3 in the peripheral blood of JAK2 V617F-
positive MPN patients is consistent with a previous report [16] and
is also expected, given existing information on the JAK–STAT
signaling pathway [3–5]. In this study, we demonstrated that,
unlike SOCS1 mRNA, SOCS3 mRNA expression level was clearly
correlated with the JAK2 V617F mutation burden and therefore,
has a potential diagnostic value as a substitute for JAK2 sequence
analysis. Consistency between PCR array and individual qPCR
assays for SOCS3, SOCS1, and SPI1 provided us with a proof of the
principle of the PCR array assay.
Our quantitation of SOCS3 mRNA does not require fractionation
of mononuclear cells or granulocytes in peripheral blood. Patient
b l o o ds a m p l e sc a nb es t o r e df o ru pt o1m o n t ha t4 uCo rf o r3d a y sa t
ambient temperature once they have been mixed with the RNAlater
solution for RNA stabilization. Our SOCS3 mRNA quantitation
procedure is also straightforward compared with the use of SOCS3
phosphorylation in sorted cell populations [17] and is suitable for use
as a biomarker of JAK2 activation.
SPI1 encodes the ETS family transcription factor PU.1, which is
necessary for erythroid, myeloid, and lymphoid differentiation [6].
The target genes of PU.1 include those encoding IL-7 receptor a
(IL-7Ra), macrophage colony stimulating factor receptor (M-
CSFR), G-CSF receptor (G-CSFR), and granulocyte macrophage
colony stimulating factor receptor a (GM-CSFRa). As ligand-
engaged IL-7Ra recruits JAK1 and JAK3 and activates STAT5,
PU.1 may activate STAT5 in developing lymphocytes. In
developing erythrocytes, however, PU.1 deficiency does not affect
the amount or phosphorylation status of STAT5 [18]. PU.1 is
known to cooperate with STAT1 in promoter binding and
transcriptional activation of the FCGR1 gene encoding Fcc
receptor I [19]. PU.1 is also implicated in erythroleukemogenesis
as PU.1 transgenic mice exhibit proliferation of proerythroblasts
[20]. The reported link between PU.1 and cyclin-dependent
kinase 6 (CDK6) may explain the oncogenic potential of this
transcription factor [21].
It is noteworthy that other ETS transcription factors, such as.
ERG, ETV1, ETV4, ETV6, FLI1, and FEV, are implicated in the
pathogenesis of several cancers. For example, ETV6 (also known as
TEL) are occasionally fused with RUNX1 (also known as AML1)i n
childhood precursor B-cell acute lymphoblastic leukemia [22]. Gene
fusions found in prostate cancer often involve the ERG, ETV1,o r
ETV4 gene [23]. Most Ewing sarcomas harbor gene fusions involving
the FLI1, ERG, ETV1, ETV4,o rFEV gene [24]. These reports
suggest an oncogenic role of ETS transcription factors in general.
Involvement of ETS transcription factors in PV is not surprising,
given that its name is derived from that of the avian erythroblastosis
virus, E26, which carries the v-ets (E Twenty-Six) oncogene [25].
There have been extensive studies on gene regulatory elements
for PU.1 expression. They have demonstrated that PU.1 is
regulated by Oct-1, Sp1, GATA-1, SpiB, and PU.1 itself [6].
Notch1 also directly regulates PU.1 expression [26]. We observed
increased SPI1/PU.1 expression in peripheral blood of our MPN
patients. This increase was correlated with the JAK2 V617F-
mutation burden. Overexpression of the JAK2 V617F mutant but
not the wild-type JAK2 in K562 cells also resulted in increased
SPI1 expression. RNAi against JAK2 reduced SPI1 expression in
JAK2 V617F-positive HEL cells. Therefore, our data are the first
to suggest that SPI1 expression is regulated by JAK2 in humans,
possibly through STAT3, STAT5A, or STAT5B (Figure 6).
Consistent with this hypothesis, upregulation of SPI1/PU.1 by
GM-CSF, which also activates JAK2, in alveolar macrophages has
been reported [27].
Figure 4. Reduction of SOCS3 and SPI1 mRNA in HEL cells
transfected with JAK2 siRNAs. A. Western blots of JAK2 protein in
HEL and K562 cells treated with siRNAs against JAK2 are shown. EF-2
was detected as a loading control. Cell lysates were prepared 24 h after
siRNA transfection. Proteins derived from 1610
5 cells were loaded onto
each lane. Alexa 680-labeled secondary antibodies were used. Three
types of siRNA against JAK2 (siRNA1–3) and a negative control siRNA
(NC1) are described in the Materials and Methods section. Fold change
represents a ratio of band intensity of JAK2 and that of EF-2. B. SOCS3
mRNA amount determined by qPCR. RNA was prepared 48 h after
siRNA transfection. The values are expressed with an arbitrary unit as
the mean of NC1 and NC2-treated HEL cells as 1. Error bars represent
standard errors for triplicate measurements. C. SPI1 mRNA amount
shown as in B.
doi:10.1371/journal.pone.0022148.g004
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JAK2 but also by pharmacological inhibition of ABL1. Since both
JAK2 and ABL1 activate STAT3 and STAT5 [13,14], SPI1
expression may be mediated through STAT3 or STAT5. This
speculation is consistent with reported reduction of SPI1
expression after BCR-ABL1 inhibition by RNA interference or
protein chaperon blockade in K562 [28,29]. The lack of SPI1
downregulation in AG490-treated HEL cells is difficult to interpret
because of the possibility that the reduction of JAK2 signaling was
insulated by attenuated negative feedback by SOCS3. In contrast
to JAK2 inhibition by AG490, which affects the entire cell
population, but may be incomplete, JAK2 knockdown by siRNA
only affects the cells that incorporated siRNA. Considering the
efficiency of siRNA transfection (approximately 60% of cells were
positive 3 h after electroporation with fluorescence-labeled control
siRNA) and overall reduction of JAK2 amount (approximately
80% for siRNA3, Figure 4A), suppression of JAK2 protein
expression in individual cells may have progressed enough to
prevent reversal by the weakened negative feedback by SOCS3.
Refractoriness of downstream gene expression against upstream
Figure 5. Effect of pharmacological inhibition of JAK2 and ABL1 kinases on SOCS3 and SPI1 expression. A. Western blots of total JAK2
and phosphorylated JAK2 (P-JAK2) are shown. EF-2 was detected as a loading control. Cell lysates were prepared 24 h after addition of indicated
concentrations of AG490 to the culture medium. Proteins derived from 5610
5 cells were loaded onto each lane. Horseradish peroxidase-labeled
secondary antibodies were used. B. SOCS3 and SPI1 mRNA amount determined by qPCR in cells 24 h after addition of indicated concentrations of
AG490. The values are expressed with an arbitrary unit. Data at 48 h were similar (not shown). C. SOCS3 and SPI1 mRNA amount determined by qPCR
in cells 48 h after addition of indicated concentrations of imatinib. The values are expressed with an arbitrary unit.
doi:10.1371/journal.pone.0022148.g005
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pathways with negative feedback mechanisms like that of SOCS3.
This point should be considered when pathway-targeted therapies
are designed. In a study using zebrafish embryos where spi1 was
reduced by a JAK2 antisense oligonucleotide [11], the effect of
AG490 on spi1 expression was not presented.
In this study, we did not analyze the genes downregulated in
MPN patients in depth. Many of these downregulated genes were
differentially expressed independent of JAK2 mutations (Table 2),
and further analysis of these genes may provide clues to the
pathophysiology of MPN.
To summarize, examination of the expression profiles of 84 JAK–
STAT-related genes in peripheral blood of MPN patients identified
2 upregulated genes. One is a known target, SOCS3, and the other is
a potentially novel JAK–STAT target, SPI1, encoding the
transcription factor PU.1. In addition to JAK2, ABL1 kinase may
induce SPI1 expression. Molecular analysis of patient samples such
as those reported here will facilitate further understanding of
hematological diseases and eventually lead to improved patient care.
Supporting Information
Figure S1 A. Proliferation of HEL and K562 cells in the presence
of indicated concentrations of AG490 subjected to expression
analysis in Figures 5A and 5B was assessed by hemocytometer with
trypan blue exclusion. Cell concentration is divided by the initial
concentration of 4610
5 cell/ml and represented as the magnitude
of change.B. Proliferationof HEL and K562cells in the presence of
imanitib subjected to expression analysis in Figure 5C was assessed
by hemocytometer with trypan blue exclusion. Cell concentration is
divided by the initial concentration of 2.5610
5 cell/ml and
represented as the magnitude of change.
(TIF)
Table S1 Patient List. Summary of clinical data and JAK2
V617F test for the 26 patients is shown. The normal range of each test
is indicated in the brackets with female (F) or male (M)-specific ranges if
available. Data are shown in 2 lines: upper is the data at the time of
blood sampling for JAK2 V617F mutation analysis and RNA
preparation, and the lower within parentheses are those upon
diagnosis. Treatment indicates administration of medication or
bloodletting: HU for hydroxyurea, AP for allopurinol, AS for aspirin,
and BL for bloodletting at the time of blood sampling. ‘‘No’’ treatments
indicates that the patient was diagnosed freshly and had no previous
history of treatment for MPN. Time from diagnosis to blood sampling
for this study is indicated in months. Other abbreviations are: PV,
polycythemia vera; ET, essential thrombocythemia; AS PCR, allele-
specific PCR; WBC, white blood cell; RBC, red blood cell; Hb,
hemoglobin; Ht, hematocrit; and PLT, platelet.
(XLS)
Table S2 PCR primer sequence. The primer sequences used
in this study are shown.
(XLS)
Table S3 PCR array data for analysis. The PCR array data
from 26 MPN patients (M plus number) and 11 healthy volunteers
(N plus number) are shown. We analyzed this table using a web-
based tool (RT2 Profiler) provided by SABiosciences.
(XLS)
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